by dyadic | Nov 21, 2024 | Press Releases
Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable TherapeuticsJUPITER, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced today that it has been...
by dyadic | Nov 12, 2024 | Press Releases
Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Alternative Proteins Demonstrated substantial revenue increase for Q3 2024, driven primarily by Dapibus™ license...
by dyadic | Nov 4, 2024 | Press Releases
JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale...
by dyadic | Oct 9, 2024 | Press Releases
JUPITER, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the large-scale, efficient manufacturing of proteins for human and animal vaccines,...
by dyadic | Sep 23, 2024 | Press Releases
JUPITER, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient, large-scale...
